These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28194882)

  • 61. [Efficacy and safety of low molecular weight heparin in the treatment of pulmonary thromboembolism].
    Cereza G; Danés I
    Med Clin (Barc); 1999 Jun; 113(3):115-6. PubMed ID: 10464747
    [No Abstract]   [Full Text] [Related]  

  • 62. Low-molecular-weight heparin for the treatment of deep vein thrombosis.
    Thompson-Ford JK
    Pharmacotherapy; 1998; 18(4):748-58. PubMed ID: 9692649
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Guideline update. VTE disease: which agents, and when.
    Holten KB; Merok J
    J Fam Pract; 2009 Mar; 58(3):E1. PubMed ID: 19284934
    [No Abstract]   [Full Text] [Related]  

  • 64. [LMWH and UFH in direct comparison. Consent: CERTIFY].
    MMW Fortschr Med; 2007 May; 149(20):53. PubMed ID: 18051967
    [No Abstract]   [Full Text] [Related]  

  • 65. Management of unstable coronary-artery disease.
    Cohen AT
    Lancet; 2000 Feb; 355(9203):574. PubMed ID: 10683025
    [No Abstract]   [Full Text] [Related]  

  • 66. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
    van der Heijden JF; Hutten BA; Büller HR; Prins MH
    Cochrane Database Syst Rev; 2002; (1):CD002001. PubMed ID: 11869618
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring.
    Hull RD; Pineo GF; Stein P
    Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
    Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants.
    Iorio A; Guercini F; Pini M
    J Thromb Haemost; 2003 Sep; 1(9):1906-13. PubMed ID: 12941030
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prophylaxis of catheter-related thrombosis in cancer patients.
    Prandoni P
    Lancet; 2009 Feb; 373(9663):523-4. PubMed ID: 19217973
    [No Abstract]   [Full Text] [Related]  

  • 71. Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome.
    Kaandorp S; Di Nisio M; Goddijn M; Middeldorp S
    Cochrane Database Syst Rev; 2009 Jan; (1):CD004734. PubMed ID: 19160241
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Should patients with venous thromboembolism and cancer be treated differently?
    Smorenburg SM; Hutten BA; Prins MH
    Haemostasis; 1999 Dec; 29 Suppl S1():91-7. PubMed ID: 10629414
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [The treatment with low-molecular-weight heparin of disseminated intravascular coagulation secondary to an aortic aneurysm].
    Callejas Rubio JL; Ortego Centeno N; Díez Ruiz A; Bermúdez García JM
    Rev Clin Esp; 1998 Nov; 198(11):781-2. PubMed ID: 9883061
    [No Abstract]   [Full Text] [Related]  

  • 74. Use of anticoagulants in ST-segment elevation myocardial infarction patients; a focus on low-molecular-weight heparin.
    Gurm HS; Eagle KA
    Cardiovasc Drugs Ther; 2008 Feb; 22(1):59-69. PubMed ID: 18165932
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis.
    Kodumuri V; Adigopula S; Singh P; Swaminathan P; Arora R; Khosla S
    Am J Ther; 2011 May; 18(3):180-9. PubMed ID: 20027109
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Low-molecular-weight heparin: from the bench to the orthopedic patient.
    Turpie AG
    Orthopedics; 1997 Feb; 20 Suppl():10-3. PubMed ID: 9048401
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
    Andras A; Sala Tenna A; Stewart M
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002001. PubMed ID: 28737834
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Low-molecular-weight heparin in preventing and treating DVT.
    Rydberg EJ; Westfall JM; Nicholas RA
    Am Fam Physician; 1999 Mar; 59(6):1607-12. PubMed ID: 10193600
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis.
    Zarychanski R; Abou-Setta AM; Kanji S; Turgeon AF; Kumar A; Houston DS; Rimmer E; Houston BL; McIntyre L; Fox-Robichaud AE; Hébert P; Cook DJ; Fergusson DA;
    Crit Care Med; 2015 Mar; 43(3):511-8. PubMed ID: 25493972
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Thromboembolism.
    Fitzmaurice D; Hobbs FD; McManus R
    Clin Evid; 2002 Jun; (7):199-213. PubMed ID: 12230644
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.